Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry

 April 2, 2026

Pharmaceutical Technology

Lilly’s product, known under the brand name Foundayo, has a clear route to early blockbuster status.

RegulatoryMetabolic & GLP-1Read full story

Post navigation

Building What’s Next: Join Industry Leaders to Shape Access and Affordability Trends Ahead of Asembia AXS26 →
← ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com